India's Biocon climbs on unit's deal for branded formulations business
** Shares of Biocon BION.NS settles 5.8% higher at 267.40
rupees
** Unit Biocon Biologics to transfer branded formulations
business in India to Eris Lifesciences ERIS.NS in a 12.42 bln
rupees ($150 mln) deal
** BION rose as much as 8.2% after the announcement
** ERIS settled 3.8% higher
** BION up ~7% YTD, vs a ~12% rise in Nifty Pharma index
.NIPHARM
($1 = 82.8170 Indian rupees)
(Reporting by Nishit Navin)
((nishit.navin@thomsonreuters.com;))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees